课题基金 / 基金详情

Amotosalen PCT of Leukapheresis Units for GvHD Therapy

Amotosalen PCT of Leukapheresis Units for GvHD Therapy
用于 GvHD 治疗的白细胞分离装置 Amotosalen PCT
批准号:
6787862
负责人:
JOHN E HEARST
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-09-01 至 2007-08-31

项目摘要

项目成果

JOHN E HEARST的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):这是一个合并的I/II期SBIR快速通道提案。骨髓移植有可能完全治愈血液系统恶性肿瘤的疾病症状,并最终以适当的安全性特征治愈血红蛋白病的症状。即使在相关的完全匹配的骨髓移植的情况下,也存在与移植物抗宿主病(GvHD)相关的发病率和死亡率。错配(相关-单倍体相合和无关)骨髓移植在白血病或淋巴瘤患者中的成功应用需要获得改善的BMT总体结局,以及避免或成功治疗现有错配骨髓移植(BMT)方案中出现的GvHD。这两个目标可能需要使用低强度预处理(RIC)方案来支持移植。体外光采(ECP)已被证明是有效的移植后GvHD的治疗方式,并作为一种治疗方案越来越受欢迎。该SBIR建议旨在开发一种更简单且更便宜的方法,用于移植患者自体白细胞的光化学处理,这将有助于确定临床反应所需的光化学处理细胞的治疗剂量,所述临床反应等同于使用目前批准的ECP仪器和方案观察到的反应。本申请的第I阶段将建立体外光化学给药和监管验证,这是向FDA成功提交新版ECP IND申请所需的。第二阶段将支持临床试验,作为该方案和产品获得监管批准的第一步。I期临床试验将是在Tufts-New England Medical Center进行的单一研究者试验,由Francine Foss博士担任研究的主要研究者。Cerus公司是世界领先的临床应用光化学的公司。我们最近完成了一项研究,通过支持美国公共卫生服务基金R 01 HL 63456,“干细胞移植建立异源嵌合体。“此外,我们还参与了三项临床试验,这些试验利用Amotosalen-HCI光化学处理的白细胞用于骨髓移植和作为EB病毒疫苗。
英文摘要
DESCRIPTION (provided by applicant): This is a combined Phase I/II SBIR Fast-Track proposal. Bone marrow transplantation has the potential of providing a complete cure of the disease symptoms of hematologic malignancies and, ultimately, with an appropriate safety profile, the symptoms of hemoglobinopathies as well. Even in the case of related fully matched bone marrow transplantation, there is morbidity and mortality associated with Graft-versus- Host-Disease (GvHD). Successful application of mismatched (related-haploidentical and unrelated) Bone Marrow Transplantation to patients with leukemia or lymphoma requires that improved overall outcomes of the BMT be obtained, coupled with the avoidance or successful treatment for the GvHD now experienced in existing mismatched bone marrow transplantation (BMT) protocols. These two goals may require use of reduced-intensity conditioning (RIC) regimens in support of the transplantation. Extracorporeal Photopheresis (ECP) has proved to be effective as a treatment modality for GvHD following transplantation and is gaining popularity as a treatment protocol. This SBIR proposal is directed at the development of a more simple and less expensive process for the psoralen photochemical treatment of the transplant patient's autologous leukocytes which will help define the therapeutic dose of photochemically treated cells required for clinical responses equivalent to those which have been observed using present approved ECP instrumentation and protocols. Phase I of this application will establish the in vitro photochemical dosing and the regulatory validations, which will be required for a successful IND application to the FDA for this new version of ECP. Phase II will support a clinical trial as a first step toward regulatory approval of this protocol and product. The Phase I Clinical Trial will be a single investigator trial at the Tufts-New England Medical Center with Dr. Francine Foss as the Lead Investigator of the study. Cerus Corporation is the world's leader in the application of psoralen photochemistry in the clinic. We have recently completed a study through the support of US Public Health Service Grant R01 HL63456, "Stem Cell Transplantation to Establish Allochimerism." In addition we are associated with three clinical trials utilizing Amotosalen-HCI photochemically treated leukocytes for use in bone marrow transplantation and as a vaccine for Epstein-Barr virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MINIATURIZED INSTRUMENTATION FOR THE HTS OF DNA REPAIR
  • 批准号:
    6738364
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2004
  • 负责人:
    JOHN E HEARST
  • 依托单位:
Amotosalen PCT of Leukapheresis Units for GvHD Therapy
Cord Blood Stem Cell Transplantation, Hemoglobinopathies
  • 批准号:
    6689114
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2003
  • 负责人:
    JOHN E HEARST
  • 依托单位:
DNA Repair Inhibition and Cancer Therapy
  • 批准号:
    6691226
  • 项目类别:
  • 资助金额:
    $10.0万
  • 财政年份:
    2003
  • 负责人:
    JOHN E HEARST
  • 依托单位:
海外基金